Allergan Again Blasts Valeant Bid As Investors Urge Talks
Despite a third high-profile shareholder unleashing criticism over Allergan Inc.'s refusal to consider a $53 billion offer from Valeant Pharmaceuticals International Inc., the targeted drugmaker said Monday it still believes the...To view the full article, register now.
Already a subscriber? Click here to view full article